
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is a leader in delivering customized electronic pharma messages to healthcare providers, and its differentiated ability to deliver three types of messages in the provider's EHR sets it apart from the competition. With its new programmatic connection and strong growth drivers, coupled with its impressive ability to expand margins, OptimizeRx is poised for double-digit revenue growth and continued profitability.
Bears say
OptimizeRx is expected to face continued headwinds due to macroeconomic risks and the company-specific execution issue caused by one of their top clients. Although the company has maintained their EBITDA outlook through cost actions, its organic total revenue has declined in the past few years. With 2026 revenue guidance being lowered by 13%, the company's reliance on drug approvals by FDA and its customer concentration pose additional risks. Also, the recent announcement of allowing DSPs access to their EHR network may provide incremental revenue, but the financial contribution and sizing remain uncertain. The company's 4Q25 results showed modest revenue growth, but its organic total revenue has been negative in recent years and its net revenue retention has also declined. Despite the positive gross margin outperformance and lower operating expenses, the company's future visibility is challenged due to the current headcount being able to support a lower revenue run-rate and contracted revenue being lower than historical visibility. Even though AI could potentially provide a tailwind, its impact on the financials remains unknown, and the company has not provided specific NRR guidance. Overall, given the various risks and uncertainties, OptimizeRx's stock may continue to underperform in the near term.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares